Dermata Therapeutics Stock Target Price and Analyst Consensus

DRMA -  USA Stock  

USD 1.64  0.08  4.65%

The current analyst and expert consensus on Dermata Therapeutics is Strong Buy, with 0 strong sell and 2 strong buy opinions. The current projected Dermata Therapeutics target price consensus is 11.5 with 2 analyst opinions. The most common way Dermata Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Dermata Therapeutics executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on Dermata Therapeutics. We encourage you to use your own analysis of Dermata Therapeutics to validate this buy or sell advice. Dermata Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Dermata Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 3.535. Continue to Macroaxis Advice on Dermata Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.

Dermata Analyst Recommendations 

 
Refresh

Dermata Therapeutics Target Price Consensus

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Dermata target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Dermata target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Number of Opinions2
Lowered Outlook0
Raized Outlook0
Strong Buy
Most Dermata analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Dermata stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Dermata Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Dermata Therapeutics Target Price Projection

Dermata Therapeutics' current and average target prices are 1.64 and 11.50, respectively. The current price of Dermata Therapeutics is the price at which Dermata Therapeutics is currently trading. On the other hand, Dermata Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Dermata Therapeutics Market Quote on 24th of January 2022

Low Price1.53Odds
High Price1.69Odds

1.64

Target Price

Analyst Consensus On Dermata Therapeutics Target Price

Low Estimate9.0Odds
High Estimate14.0Odds
Number of Analysts2
Standard Deviation3.535

11.5

Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Dermata Therapeutics and the information provided on this page.

Dermata Therapeutics Analyst Ratings

Dermata Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Dermata Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Dermata Therapeutics' financials, market performance, and future outlook by experienced professionals. Dermata Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.

Average Consensus Estimates

About Dermata Therapeutics Target Price Projections

Dermata Therapeutics's target price is an analyst's projection of its future price. Price targets can be assigned to all types of securities, from complex investment products to stocks such as Dermata Therapeutics and even bonds. If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. When setting a price target estimate, an analyst is trying to determine what the Stock is worth and where the price will be in a year from now. Generally, the target price of Dermata depends on its intrinsic valuation, beta (i.e., risk over market), and overall volatility. Most analysts publish their price targets in research reports on specific companies, along with their buy, hold, or sell recommendations. Stock price targets are often quoted in the financial news media. Macroaxis uses multiple feeds to provide overall target price projection for Dermata Therapeutics including its fundamental analysis.
 2010 2021 2022 (projected)
Return on Invested Capital11.5210.3710.31
Return on Average Equity1.911.721.71

Additional Dermata Therapeutics Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Dermata Therapeutics is a key component of Dermata Therapeutics valuation and have some predictive power on the future returns of a Dermata Therapeutics.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Dermata Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Dermata Therapeutics in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
0.102.0310.79
Details
Intrinsic
Valuation
LowReal ValueHigh
0.204.0912.85
Details
Naive
Forecast
LowNext ValueHigh
0.0478552.3911.15
Details
Earnings
Estimates (1)
LowProjected EPSHigh
-2.39-2.39-2.39
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Dermata Therapeutics. Your research has to be compared to or analyzed against Dermata Therapeutics' peers to derive any actionable benefits. When done correctly, Dermata Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Dermata Therapeutics.

Currently Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Macroaxis Index
Invested over 1M shares
Corona Opportunity
Invested over 1M shares
Software
Invested over 1M shares
Social Domain
Invested over 1M shares
Momentum
Invested over 1M shares
Disruptive Technologies
Invested over 1M shares
Continue to Macroaxis Advice on Dermata Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. Note that the Dermata Therapeutics information on this page should be used as a complementary analysis to other Dermata Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Dermata Stock analysis

When running Dermata Therapeutics price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
The data published in Dermata Therapeutics' official financial statements usually reflect Dermata Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Dermata Therapeutics. For example, before you start analyzing numbers published by Dermata accountants, it's critical to develop an understanding of what Dermata Therapeutics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Dermata Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Dermata Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Dermata Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dermata Therapeutics. Please utilize our Beneish M Score to check the likelihood of Dermata Therapeutics' management to manipulate its earnings.